Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, Liposomal MTP-PE, MLV 19835A, MTP-PE, Muramyltripeptide Phosphatidylethanolamine

Author： Adis International Limited  

Publisher： Adis International

ISSN： 1174-5886

Source： Drugs in R&D, Vol.9, Iss.2, 2008-01, pp. : 131-135

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Current Biology of MTP: Implications for Selective Inhibition

By  

Current Topics in Medicinal Chemistry, Vol. 5, Iss. 3, 2005-04 ,pp. : 283-300

Bentham Science Publishers

Access to resources Recommend Favorite

MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?

By Burnett John R   Watts Gerald F  

Expert Opinion on Therapeutic Targets, Vol. 11, Iss. 2, 2007-02 ,pp. : 181-189

Informa Healthcare

Access to resources Recommend Favorite

Idraparinux sodium effective for DVT, but not PE

By  

Inpharma, Vol. 1, Iss. 1570, 2007-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion

By Shiomi M.   Ito T.  

European Journal of Pharmacology, Vol. 431, Iss. 1, 2001-11 ,pp. : 127-131

Elsevier

Access to resources Recommend Favorite

Atorvastatin increases hepatic fatty acid beta-oxidation in sucrose-fed rats: comparison with an MTP inhibitor

By Funatsu T.   Kakuta H.   Takasu T.   Miyata K.  

European Journal of Pharmacology, Vol. 455, Iss. 2, 2002-11 ,pp. : 161-167

Elsevier

Access to resources Recommend Favorite